ORGO — Organogenesis Holdings Share News
0.000.00%
Last trade - 00:00- $127.80m
- $85.28m
- $564.17m
Organogenesis falls after joint disease therapy fails to meet late-stage study goal
Brief: Organogenesis Provides Update On Second Phase 3 Renu Study
Organogenesis Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Organogenesis misses Q2 revenue estimates
Organogenesis Holdings Inc expected to post a loss of 6 cents a share - Earnings Preview
Organogenesis Holdings Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Organogenesis Q1 Revenue USD 86.7 Million
Organogenesis Holdings Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Organogenesis Q4 Revenue USD 126.7 Million
Organogenesis Holdings Inc expected to post a loss of 1 cent a share - Earnings Preview
Organogenesis Holdings Inc reports results for the quarter - Earnings Summary
Brief: Organogenesis Q3 Revenue USD 115.2 Million
Organogenesis Holdings Inc expected to post a loss of 1 cent a share - Earnings Preview
Brief: Organogenesis Announces Publication Of Randomized Clinical Trial Results Of Nushield For Diabetic Foot Ulcers
Organogenesis Holdings Inc reports results for the quarter ended in January - Earnings Summary
Brief: Organogenesis Q2 Revenue USD 130.2 Million
Organogenesis Holdings Inc expected to post breakeven results a share - Earnings Preview
Organogenesis Holdings Inc reports results for the quarter ended in March - Earnings Summary
Brief: Organogenesis Q1 Revenue USD 110 Million